Trials Sponsors Conditions Drugs Pricing

Conditions

Blepharitis

Keywords

Blepharitis

Outcome Measures

Primary Outcomes (1)

Demodex mite killing
Number of living Demodex mites following treatment
From enrollment to last visit at 2 weeks

Secondary Outcomes (3)

Collarette Cure
From enrollment to last visit at 2 weeks
Erythema Cure
From enrollment to last visit at 2 weeks
Demodex mite density
From enrollment to last visit at 2 weeks

Study Arms (2)

Active

ACTIVE COMPARATOR

APT-001 topical ophthalmic ointment, administered once

Drug: APT-001 topical ophthalmic ointment (spinosad)

Placebo control for APT-001 topical ophthalmic ointment, administered once

PLACEBO COMPARATOR

Drug: Placebo control for APT-001 topical ophthalmic ointment

Interventions

APT-001 topical ophthalmic ointment (spinosad)Drug

APT-001 topical ophthalmic ointment (spinosad), administered once

Active

Placebo control for APT-001 topical ophthalmic ointmentDrug

Placebo control for APT-001 topical ophthalmic ointment, administered once

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

Symptomatic blepharitis
At least 18 years of age

Sponsors & Collaborators

Aperta Biosciences, LLC
Industrylead

Study Sites (2)

EyeScan, Imágenes Diagnósticas Oculares, S. A.

Guatemala City, Guatemala

Glendy MartinezCONTACT+502 5930-5051 Eyescangt@gmail.com

Rudy Oliver Gutierrez Paz, MDPRINCIPAL INVESTIGATOR

Hospital de Día, Clínica de Ojos Doctor Gutiérrez

Guatemala City, Guatemala

Ozen MartinezCONTACT+502-2236-4100 servicioalcliente@clinicasdrgutierrez.com

Rudy Gutierrez Diaz, MDPRINCIPAL INVESTIGATOR

MeSH Terms

Conditions

Blepharitis

Interventions

spinosad

Condition Hierarchy (Ancestors)

Eyelid DiseasesEye Diseases

Study Officials

Josue Moran, Ph.D.
Aperta Biosciences, LLC
STUDY DIRECTOR

Central Study Contacts

Josue Moran, Ph. D.

CONTACT

512-270-3960 vista@apertabio.com

Study Design

Study Type: interventional
Phase: phase 2
Allocation: NON RANDOMIZED
Masking: NONE
Purpose: TREATMENT
Intervention Model: PARALLEL
Sponsor Type: INDUSTRY
Responsible Party: SPONSOR

Study Record Dates

First Submitted

October 23, 2026

First Posted

October 29, 2026

Study Start

December 2026

Estimated

Planned date reported by the registry; this milestone is not confirmed as achieved.

Primary Completion

January 2027

Estimated

A Phase 2, Open-Label, Multicenter Study to Compare Efficacy and Safety of a Novel Topical Therapy (APT-001, Spinosad 1.8%) in Patients With Blepharitis

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (3)

Study Arms (2)

Active

Placebo control for APT-001 topical ophthalmic ointment, administered once

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (2)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (3)

Study Arms (2)

Active

Placebo control for APT-001 topical ophthalmic ointment, administered once

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (2)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations